Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Month Periods Ended |
|
Nine-Month Periods Ended |
|
|
|
October 30, |
|
October 31, |
|
October 30, |
|
October 31, |
|
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(9,492,000) |
|
$ |
(4,748,000) |
|
$ |
(16,970,000) |
|
$ |
(10,522,000) |
|
Earnings allocated to participating share awards |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Net loss attributable to common shares — Basic and diluted |
|
$ |
(9,492,000) |
|
$ |
(4,748,000) |
|
$ |
(16,970,000) |
|
$ |
(10,522,000) |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding — Basic (a) |
|
|
21,503,340 |
|
|
12,177,990 |
|
|
18,710,658 |
|
|
10,000,383 |
|
Dilutive effect of stock options, non-vested shares and warrants (b) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Weighted average number of common shares outstanding — Diluted |
|
|
21,503,340 |
|
|
12,177,990 |
|
|
18,710,658 |
|
|
10,000,383 |
|
Net loss per common share |
|
$ |
(0.44) |
|
$ |
(0.39) |
|
$ |
(0.91) |
|
$ |
(1.05) |
|
Net loss per common share — assuming dilution |
|
$ |
(0.44) |
|
$ |
(0.39) |
|
$ |
(0.91) |
|
$ |
(1.05) |
|
|
(a) |
For the three and nine-month periods ended October 30, 2021, the basic earnings per share computation included 21,000 outstanding fully-paid warrants to purchase shares of the Company’s common stock at a price of $0.001 per share.
|
|
(b) |
For the three and nine-month periods ended October 30, 2021 and October 31, 2020 there were 658,000 and 796,000 and 992,000 and 476,000 incremental in-the-money potentially dilutive common shares outstanding. The incremental in-the-money potentially dilutive common stock shares are excluded from the computation of diluted earnings per share, as the effect of their inclusion would be anti-dilutive.
|
|